Obermatt
See Similar Stocks →

Flags

Financial distress

Pacific Biosciences of California

NSQ:PACB · US69404D1081
Life Sciences Tools & ServicesSmall

360

16
Profit price49
Owner Earnings Yield1
Dividend Yield1
Price/Sales80
EV / Gross Profit20
Price/Book73
Return on Capital20
Cash Return on Capital18
Return on Equity1
EBIT Margin14
Gross Profitability14
Accruals69
Owner Earnings Margin14
Sales growth51
Profit growth31
Reinvestment65
Price momentum46
Debt load5
Refinancing93
Debt Payback1
Liquidity46
Analyst ratings12
Opinion Changes50
Price Target Upside84
Market mood41
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Pacific Biosciences of California doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2000
Employees511
Websitepacb.com
ISINUS69404D1081
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsGeneticsBiotechnologyIndustrialLife ScienceMedical

Description

Pacific Biosciences of California, Inc. operates as a life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome…

Analysis

Weak and unloved

Pacific Biosciences of California, Inc. is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 4/20 on our value-creation score: not creating value.

What to watch: A large part of the company's book value is the price paid for past acquisitions. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
30
2023202420252026

All-time high

34

Mar 2026

All-time low

10

Jan 2024

Average rank

24

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
80
68
5
13
Price/Earnings
45
40
40
8
Price/Book
73
76
40
54
Dividend Yield
1
1
1
1
Value (overall)
65
73
14
21

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Pacific Biosciences of California with its peers
Voyager Therapeutics
NSQ:VYGR
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Inotiv
NAQ:NOTV
16
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Beam Therapeutics
NSQ:BEAM
17
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Benitec Biopharma
NAQ:BNTC
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Exact Sciences
NAQ:EXAS
20
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Sangamo Therapeutics
NAQ:SGMO
34
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →